Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

Publication

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

Journal Paper/Review - Jul 19, 2016

Gillessen Sommer Silke, Gilson Clare, James Nick, Adler Amanda, Sydes Matthew R, Clarke Noel

Citation

Gillessen Sommer S, Gilson C, James N, Adler A, Sydes M, Clarke N. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. Eur Urol 2016; 70:906-908.

Type

Journal Paper/Review (English)

Journal

Eur Urol 2016; 70

Publication Date

Jul 19, 2016

Issn Electronic

1873-7560

Pages

906-908

Brief description/objective

UNASSIGNED
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.